[go: up one dir, main page]

WO2023227746A3 - Molecular signature of actinic lentigo associated with vesicle management - Google Patents

Molecular signature of actinic lentigo associated with vesicle management Download PDF

Info

Publication number
WO2023227746A3
WO2023227746A3 PCT/EP2023/064124 EP2023064124W WO2023227746A3 WO 2023227746 A3 WO2023227746 A3 WO 2023227746A3 EP 2023064124 W EP2023064124 W EP 2023064124W WO 2023227746 A3 WO2023227746 A3 WO 2023227746A3
Authority
WO
WIPO (PCT)
Prior art keywords
management
skin
vesicle
pigmentary
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2023/064124
Other languages
French (fr)
Other versions
WO2023227746A2 (en
Inventor
Emilie WARRICK
Françoise Bernerd
Charlène GAYRARD
Christine Duval
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of WO2023227746A2 publication Critical patent/WO2023227746A2/en
Publication of WO2023227746A3 publication Critical patent/WO2023227746A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a method for characterizing an apparent or suspected skin pigmentary spot in a human being, comprising the measurement of the expression levels and then comparison of the expression levels measured, in samples of skin from said spot and from adjacent non-lesioned skin, of at least one gene involved in the management of vesicles, preferably of the melanosomes, chosen from the list consisting of the genes JAKMIP2, ARC, KIF21A, SLITRK6, NRN1, SCIN, SYNPO2, TNNT1, SNTB1, ARHGAP29, RAB3IP, RHOBTB3, RASIP1, ASGR1, CHMP4C, SVIP, LRMP, NAV3 and PCLO. The invention also relates to methods for evaluating the efficacy of a treatment for pigmentary spots, to cosmetic methods for treating pigmentary spots, and also to various modulators of said genes, and to the use thereof.
PCT/EP2023/064124 2022-05-25 2023-05-25 Molecular signature of actinic lentigo associated with vesicle management Ceased WO2023227746A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2205044A FR3135992A1 (en) 2022-05-25 2022-05-25 Molecular signature of actinic lentigo associated with vesicle management
FRFR2205044 2022-05-25

Publications (2)

Publication Number Publication Date
WO2023227746A2 WO2023227746A2 (en) 2023-11-30
WO2023227746A3 true WO2023227746A3 (en) 2024-01-04

Family

ID=85222013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/064124 Ceased WO2023227746A2 (en) 2022-05-25 2023-05-25 Molecular signature of actinic lentigo associated with vesicle management

Country Status (2)

Country Link
FR (1) FR3135992A1 (en)
WO (1) WO2023227746A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140550A2 (en) * 2008-05-14 2009-11-19 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
WO2012013776A2 (en) * 2010-07-30 2012-02-02 Nestec S.A. Use of green coffee beans for regulating skin pigmentation disorders
US20120244131A1 (en) * 2011-02-04 2012-09-27 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis
FR2974370A1 (en) * 2011-04-22 2012-10-26 Oreal MOLECULAR SIGNATURE OF CUTANEOUS PIGMENT TASKS ASSOCIATED WITH THE TGF-BETA - SMAD SIGNALING PATH
US20150166646A1 (en) * 2012-06-15 2015-06-18 The Wistar Institute Of Anatomy And Biology Methods and Compositions for Treating or Diagnosing Melanoma
US20200348313A1 (en) * 2019-03-19 2020-11-05 Incyte Corporation Biomarkers for vitiligo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR332E (en) 1902-01-04 1902-12-11 Ostwald Wilhelm Manufacturing process of nitric acid
FR2974371B1 (en) 2011-04-22 2016-10-28 Oreal MOLECULAR SIGNATURE OF CUTANEOUS PIGMENTS, ASSOCIATED WITH THE FAMILY OF EXTRACELLULAR PROTEOGLYCANS AND GLYCOPROTEINS
FR2974373B1 (en) 2011-04-22 2016-09-02 Oreal MOLECULAR SIGNATURE OF CUTANEOUS PIGMENT TASKS ASSOCIATED WITH THE EXTRACELLULAR MATRIX
FR2974372B1 (en) 2011-04-22 2016-09-02 Oreal MOLECULAR SIGNATURE OF CUTANEOUS PIGMENT TASKS ASSOCIATED WITH REMODELING THE EXTRACELLULAR MATRIX

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140550A2 (en) * 2008-05-14 2009-11-19 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
WO2012013776A2 (en) * 2010-07-30 2012-02-02 Nestec S.A. Use of green coffee beans for regulating skin pigmentation disorders
US20120244131A1 (en) * 2011-02-04 2012-09-27 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis
FR2974370A1 (en) * 2011-04-22 2012-10-26 Oreal MOLECULAR SIGNATURE OF CUTANEOUS PIGMENT TASKS ASSOCIATED WITH THE TGF-BETA - SMAD SIGNALING PATH
US20150166646A1 (en) * 2012-06-15 2015-06-18 The Wistar Institute Of Anatomy And Biology Methods and Compositions for Treating or Diagnosing Melanoma
US20200348313A1 (en) * 2019-03-19 2020-11-05 Incyte Corporation Biomarkers for vitiligo

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ESPINOSA ERIC J. ET AL: "RhoBTB3: A Rho GTPase-Family ATPase Required for Endosome to Golgi Transport", CELL, vol. 137, no. 5, 29 May 2010 (2010-05-29), Amsterdam NL, pages 938 - 948, XP093105994, ISSN: 0092-8674, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801561/pdf/nihms108740.pdf> DOI: 10.1016/j.cell.2009.03.043 *
GUO WEIHONG ET AL: "Promotion of Cell Proliferation through Inhibition of Cell Autophagy Signalling Pathway by Rab3IP is Restrained by MicroRNA-532-3p in Gastric Cancer", JOURNAL OF CANCER, vol. 9, no. 23, 1 January 2018 (2018-01-01), AU, pages 4363 - 4373, XP093105955, ISSN: 1837-9664, Retrieved from the Internet <URL:https://www.jcancer.org/v09p4363.pdf> DOI: 10.7150/jca.27533 *
HUAN LIU ET AL: "Exome sequencing provides additional evidence for the involvement of ARHGAP29 in Mendelian orofacial clefting and extends the phenotypic spectrum to isolated cleft palate", BIRTH DEFECTS RESEARCH, JOHN WILEY & SONS, INC, HOBOKEN, USA, vol. 109, no. 1, 23 January 2017 (2017-01-23), pages 27 - 37, XP072279705, ISSN: 2472-1727, DOI: 10.1002/BDRA.23596 *
ORTONNE J-P: "Management of actinic lentigo and melasma: ECLAIR international study. Profile of patients, conditions and efficiency of Iklen(R) Rucinol treatment", NOUVELLES DERMATOLOGIQUES, STRASBOURG, FR, vol. 26, no. 8, 1 January 2007 (2007-01-01), pages 499 - 504, XP009093664, ISSN: 0752-5370 *
ROSSI A.B.: "Clinical and instrumental efficacy of a dermocosmetic with Uniwhite peptide, niacinamide, vitC and hyaluronic acid on reducing actinic lentigo and improving photoaging", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 74, no. 5, 31 May 2016 (2016-05-31), XP029517864, ISSN: 0190-9622, DOI: 10.1016/J.JAAD.2016.02.911 *
WARRICK E ET AL: "Morphological and molecular characterization of actinic lentigos reveals alterations of the dermal extracellular matrix", BRITISH JOURNAL OF DERMATOLOGY, JOHN WILEY, HOBOKEN, USA, vol. 177, no. 6, 16 November 2017 (2017-11-16), pages 1619 - 1632, XP071054051, ISSN: 0007-0963, DOI: 10.1111/BJD.15697 *
WARRICK E ET AL: "Supplementary information 1 for "Morphological and molecular characterization of actinic lentigos reveals alterations of the dermal extracellular matrix"", BRITISH JOURNAL OF DERMATOLOGY, 1 June 2017 (2017-06-01), pages 1 - 12, XP093037680, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Fbjd.15697&file=bjd15697-sup-0001-Supinfo1.pdf> [retrieved on 20230405] *
WARRICK E ET AL: "Supplementary Material 2 for "Morphological and molecular characterization of actinic lentigos reveals alterations of the dermal extracellular matrix"", BRITISH JOURNAL OF DERMATOLOGY, 1 June 2017 (2017-06-01), pages 1 - 3, XP093037681, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Fbjd.15697&file=bjd15697-sup-0002-Supinfo2.pdf> [retrieved on 20230405] *
WU ZHIQIANG ET AL: "Identification of Glutaminyl Cyclase isoenzyme isoQC as a regulator of SIRP[alpha]-CD47 axis", CELL RESEARCH, SPRINGER SINGAPORE, SINGAPORE, vol. 29, no. 6, 14 May 2019 (2019-05-14), pages 502 - 505, XP036854726, ISSN: 1001-0602, [retrieved on 20190514], DOI: 10.1038/S41422-019-0177-0 *

Also Published As

Publication number Publication date
WO2023227746A2 (en) 2023-11-30
FR3135992A1 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
Chitsazzadeh et al. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates
Ben-Hamo et al. MicroRNA regulation of molecular pathways as a generic mechanism and as a core disease phenotype
Chen et al. NSD2 circular RNA promotes metastasis of colorectal cancer by targeting miR‐199b‐5p‐mediated DDR1 and JAG1 signalling
Hsu et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases
Cortés-López et al. High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance
Nakatani et al. miR‐34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo‐sensitivity and malignancy
Li et al. Transcriptome analysis reveals distinct patterns of long noncoding RNAs in heart and plasma of mice with heart failure
Rai et al. DNA demethylase activity maintains intestinal cells in an undifferentiated state following loss of APC
Mao et al. Organization of DNA damage, excision repair, and mutagenesis in chromatin: A genomic perspective
McMillan et al. The use of DNA double-strand break quantification in radiotherapy
Yamada et al. UV irradiation‐induced DNA hypomethylation around WNT1 gene: Implications for solar lentigines
Selvam et al. Detecting recurrent passenger mutations in melanoma by targeted UV damage sequencing
Anbar et al. The hair follicle melanocytes in vitiligo in relation to disease duration
Han et al. Epigenetic silencing of the Wnt antagonist APCDD1 by promoter DNA hyper-methylation contributes to osteosarcoma cell invasion and metastasis
WO2023227746A3 (en) Molecular signature of actinic lentigo associated with vesicle management
Myacheva et al. CRISPRi screening identifies CASP8AP2 as an essential viability factor in lung cancer controlling tumor cell death via the AP-1 pathway
Huang et al. ARHI, as a novel suppressor of cell growth and downregulated in human hepatocellular carcinoma, could contribute to hepatocarcinogenesis
Ben Mrid et al. The emerging roles of aberrant alternative splicing in glioma
Badodi et al. Epigenetic mechanisms in paediatric brain tumours: regulators lose control
Malousi et al. Age-dependent methylation in epigenetic clock CpGs is associated with G-quadruplex, co-transcriptionally formed RNA structures and tentative splice sites
Tan et al. Amplification and overexpression of PPFIA1, a putative 11q13 invasion suppressor gene, in head and neck squamous cell carcinoma
Hansen et al. Q-nexus: a comprehensive and efficient analysis pipeline designed for ChIP-nexus
Wang et al. Epigenetic silencing of SOD2 exacerbates mitochondrial oxidative stress and promotes pulmonary fibrosis
Yu et al. The role of human antigen R (HuR) in modulating proliferation, senescence and radiosensitivity of skin cells
Felip et al. Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers?

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23729712

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23729712

Country of ref document: EP

Kind code of ref document: A2